10X Genomics

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company’s products include Single Cell Gene Expression, Immune Profiling, ATAC, and Genome. The company was founded by Serge Saxonov, Ben Hindson and Kevin D. Ness on July 2, 2012 and is headquartered in Pleasanton, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

10X Genomics reports solid earnings, eyes growth through innovation

10X Genomics delivered solid earnings in Q4 2022, with revenue growth and strong product innovation driving market presence and customer engagement.
Despite challenges like operational constraints and margin expectations, the company focuses on financial sustainability and market adaptability for future growth.
Opportunities lie in new sample types exploration, product success with Xenium and Visium HD, and customer response to Chromium Flex, indicating potential for revenue growth and market expansion.
Balanced guidance discussions and a focus on key products position 10X Genomics for strategic growth in 2023, with a global market outlook and emphasis on innovation and customer satisfaction.

10x Genomics reports robust Q1 revenue growth, eyes operational efficiency

10x Genomics delivered strong revenue growth in Q1 2023, driven by spatial portfolio and Chromium consumables, with raised revenue guidance for the year.
The company faces challenges in China and margin pressures but sees opportunities in product enhancements, market expansion, and revenue diversification.
Overall, 10x Genomics is strategically positioned for growth, with a focus on operational efficiency, customer adoption, and revenue optimization.

10X Genomics reports robust Q2 growth amidst China challenges

10X Genomics saw strong revenue growth in Q2 2023, driven by single cell and spatial portfolios.
While facing challenges in China, opportunities lie in expanding applications and clinical adoption.
Operational improvements and product advancements position the company for future growth.
Focus on margin improvement and revenue diversification key for sustained success.

10x Genomics reports robust Q3 revenue growth and strategic realignment

10x Genomics showcased strong revenue growth driven by Xenium's success, with plans to enhance product offerings and rebalance resources for future growth.
Despite challenges in gross margin and flat Chromium revenue, the company remains optimistic about its outlook and growth potential in spatial placements.
Opportunities lie in leveraging Xenium's capabilities, driving consumable revenue through discounts, and focusing on the Chromium franchise for sustained growth.

10x Genomics reports strong Q4 earnings, eyes growth opportunities

10x Genomics anticipates revenue of $670-690 million for 2024.
Guidance philosophy balances upsides and downsides for growth.
Strategic focus on product portfolio and long-term gross margin profile.
Emphasis on investments for future growth and maintaining innovation.

10x Genomics reports Q1 revenue growth, tackles pricing challenges

10x Genomics saw strong revenue growth in spatial but faced challenges with new Chromium technology orders.
The company aims to drive adoption by reducing prices and expanding the total market for single-cell technology.
Customers are showing interest in multiple platforms, setting up genomics infrastructure with various use cases.
Despite obstacles, 10x Genomics remains optimistic about the potential of its technology platforms and market growth.

10X Genomics reports Q3 revenue decline, focuses on growth strategies

10X Genomics faced revenue decline in Q3 due to sales restructuring and cautious customer spending, with full-year revenue expected to decline by 3%. Despite challenges, the company is focused on driving growth through new product launches, evolving commercial structure, and expanding access to single cell analysis. Confidence in the company's path forward remains strong, with expectations for sequential improvements and a focus on long-term opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Barcode Enabled Antigen Mapping (BEAM) screens multiple antigens against thousands of B- or T-cells to identify novel and rare antigen-specific repertoires PLEASANTON, Calif. , Nov. 9, 2022 /PRNewswire/ --  10x Genomics, Inc.  (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced the commercial availability of BEAM (Barcode Enabled Antigen Mapping), a kitted solution for antibody and T-cell receptor (TCR) discovery.

10x Genomics Launches BEAM to Improve and Streamline Antibody and T-Cell Receptor Discovery

10x Genomics, Inc. (NASDAQ:TXG ) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET Company Participants Cassie Corneau - Head, Investor Relations & Strategic Finance Serge Saxonov - Chief Executive Officer & Co-Founder Justin McAnear - Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Dan Arias - Stifel Patrick Donnelly - Citi Kyle Mikson - Canaccord Genuity Dan Brennan - Cowen Julia Qin - JPMorgan Michael Ryskin - Bank of America Matt Sykes - Goldman Sachs Operator Good evening and thank you for attending today's 10x Genomics Third Quarter 2022 Earnings Conference Call. My name is Daniel and I will be your moderator for today's call.

10x Genomics, Inc. (TXG) Q3 2022 Earnings Call Transcript

PLEASANTON, Calif. , Nov. 2, 2022 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the third quarter ended September 30, 2022.

10x Genomics Reports Third Quarter 2022 Financial Results

PLEASANTON, Calif., Oct. 31, 2022 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG) today announced it will host an Investor Day on December 8, 2022 at the company's headquarters in Pleasanton, CA starting at 9:00 a.m.

10x Genomics to Host Investor Day on December 8, 2022

Gold Fields Ltd.

Barrick Gold

There's nothing wrong with holding a portfolio consisting of boring stocks. You know, the kind of steady blue-chip stocks that don't necessarily perform as well in a bull market but hold steady in a bear market?

3 Boring Stocks with Exciting Profit Potential

PLEASANTON, Calif. , Oct. 12, 2022 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the third quarter 2022 after market close on Wednesday, November 2, 2022.

10x Genomics to Report Third Quarter Financial Results on November 2, 2022

Twist Bioscience Corp

Their long-term plans are ambitious, but they haven't performed well as investments recently.

Got $2,000? Consider Buying These 2 Beaten-Down Cathie Wood Stocks at Your Own Risk

Affirm

Aurora Innovation

Coinbase

GoodRx Holdings

Kornit Digital

Matterport

Novavax

TuSimple Holdings

Upstart Holdings

The best performer on this list has lost three-fourths of its value this year.

Should You Buy the Nasdaq's 10 Worst-Performing 2022 Stocks?

PLEASANTON, Calif. , Sept. 2, 2022 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced the company will be participating in the upcoming Morgan Stanley 20th Annual Global Healthcare Conference in New York, New York.

10x Genomics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

10x Genomics, Inc. (NASDAQ:TXG ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Cassie Corneau - Investor Relations and Strategic Finance Serge Saxonov - Chief Executive Officer & Co-founder Jim Wilbur - Chief Commercial Officer Justin McAnear - Chief Financial Officer Conference Call Participants Matt Sykes - Goldman Sachs Michael Ryskin - Bank of America Daniel Arias - Stifel Tejas Savant - Morgan Stanley Patrick Donnelly - Citi Daniel Brennan - Cowen Julia Qin - JP Morgan Matthew Larew - William Blair Kyle Mikson - Canaccord Genuity Operator Good afternoon. Thank you for attending the 10x Genomics Second Quarter Earnings Call.

10x Genomics, Inc. (TXG) CEO Serge Saxonov on Q2 2022 Results - Earnings Call Transcript

PLEASANTON, Calif. , Aug. 8, 2022 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the second quarter ended June 30, 2022.

10x Genomics Reports Second Quarter 2022 Financial Results

Torex Gold Resources, Inc. (OTCPK:TORXF) Q2 2022 Earnings Conference Call August 4, 2022 9:00 AM ET Company Participants Dan Rollins - SVP, Corporate Development & IR Jody Kuzenko - President & CEO Andrew Snowden - CFO Dave Stefanuto - EVP, Technical Services & Capital Projects Conference Call Participants Trevor Turnbull - Scotia Capital Wayne Lam - RBC Capital markets Don DeMarco - National Bank Financial Operator Thank you for standing by. This is the conference operator.

Torex Gold Resources' (TORXF) CEO Jody Kuzenko on Q2 2022 Results - Earnings Call Transcript

10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate 10x Genomics (TXG) to Report a Decline in Earnings: What to Look Out for

PLEASANTON, Calif. , July 28, 2022 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ: TXG), a life sciences leader focused on mastering biology to advance human health, today announced the company will be participating in the upcoming UBS Genomics 2.0 and MedTech Innovations Summit in Dana Point, California.

10x Genomics to Present at the UBS Genomics 2.0 and MedTech Innovations Summit

Cytek Biosciences

Cytek and 10x Genomics both offer single cell visualization tools, a growing and important field in modern medicine. However, each company sees huge differences in popularity, financial performance, and valuation, leading to a significant difference in outlook.

Cytek Biosciences Vs. 10x Genomics: 2 Opposing Cell Visualization Investments

Shares of 10x Genomics Inc. TGX, -4.32% plunged 22.3% in active morning trading Friday, putting them on track to suffer a record one-day drop to a record low Friday, after the biotechnology company's revenue warning prompted BofA Securities analyst Derik de Bruin to turn bearish. Trading volume was 3.9 million shares, already about triple the full-day average of about 1.3 million shares.

10x Genomics stock suffering record drop toward record low after revenue warnings prompts downgrade

10X Genomics Inc (NASDAQ: TXG) reported preliminary second-quarter revenue is expected to be ~$114.5 million, a decrease of 1% year-over-year, below the consensus of $127.7 million. The company sees America's revenue of ~$70.9 million (+8% Y/Y), EMEA ~$25.6 million (-11% Y/Y),.

10X Genomics Reports Q2 Preliminary Revenues, Shares Plummet On Missing Street Expectation

Shares of 10x Genomics Inc. TXG, -7.74% fell in the extended session Thursday after the biotech company said it expects second-quarter revenue to come in below Wall Street expectations. 10x Genomics shares dropped 15% after hours, following a 7.7% drop in the regular session to close at $43.29.

10x Genomics stock falls as revenue forecast disappoints

PLEASANTON, Calif. , July 14, 2022 /PRNewswire/ -- Following a comprehensive search process, 10x Genomics, Inc. (Nasdaq: TXG), today announced the hiring of Jim Wilbur, Ph.D.

10x Genomics Names Jim Wilbur as Chief Commercial Officer

PLEASANTON, Calif. , July 14, 2022 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced that its preliminary revenue is expected to be approximately $114.5 million for the second quarter ended June 30, 2022.

10x Genomics Announces Preliminary Second Quarter 2022 Revenue

PerkinElmer

Thermo Fisher Scientific

Here we look at three stocks, PKI, TMO and TXG, with robust genome sequencing capabilities that investors can keep a watch on.

3 Gene Sequencing Stocks With Potential to Gain in 2H22

Bruker

Etsy

Marriott

Insulet

SolarEdge Technologies

These seven of the best stocks to buy in June. TXG, BRKR, ETSY, PODD, MAR, RH and SEDG can make excellent investments.

7 Stocks to Buy That Could Make You a Millionaire

Demonstrates first-ever commercial product capable of single-cell RNA sequencing on FFPE tissues Opens preorders for CytAssist, the company's first spatial instrument Shares new data on the company's Xenium In Situ Analyzer, expected to ship by year-end PLEASANTON, Calif. , June 7, 2022 /PRNewswire/ -- 10x Genomics , Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced a series of product updates that will be presented at the 2022 Advances in Genome Biology and Technology (AGBT) General Meeting this week in Orlando, Fla.

10x Genomics Advances Leadership and Innovation in Single Cell and Spatial Technologies at 2022 AGBT General Meeting

Beam Therapeutics

Recursion Pharmaceuticals

Here's why our roundtable likes 10x Genomics, Beam Therapeutics, and Recursion Pharmaceuticals.

3 Cathie Wood Stocks That Could Deliver Monster Returns

Axsome Therapeutics

Doximity

Here's why three Fool.com contributors love 10x Genomics, Axsome Therapeutics, and Doximity.

News for 10X Genomics Stock (TXG)